Administration of FeTPPS significantly attenuates HMGB1- and caspase-11–mediated GSDMD cleavage, organ damage, and lethality in endotoxemia and bacterial sepsis. The gene discussed is HMGB1; the disease is serum lipopolysaccharide activity.